Hospital Universitario 12 de Octubre-ko ikertzaileekin lankidetzan egindako argitalpenak (144)

2026

  1. A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry

    HemaSphere

  2. Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma

    Journal for immunotherapy of cancer, Vol. 14, Núm. 3

  3. BLOOD-BASED RISK STRATIFICATION OF MYELOMA PATIENTS USING CIRCULATING TUMOR CELLS: RESULTS FROM THE EUROPEAN CTC CONSORTIUM

    Haematologica, Vol. 111

  4. Comparative Efficacy of Talquetamab vs. Real-World Physician’s Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent

    Advances in Therapy, Vol. 43, Núm. 1, pp. 333-355

  5. Immune biomarkers of increased infection risk in multiple myeloma

    Blood, Vol. 147, Núm. 18, pp. 2081-2088

  6. Plain language summary of a study on 30-minute intravenous infusion of isatuximab in people with newly diagnosed multiple myeloma

    Future Oncology, Vol. 22, Núm. 11, pp. 1235-1246

  7. Real-world evidence of measurable residual disease assessment in multiple myeloma

    Blood Advances, Vol. 10, Núm. 5, pp. 1559-1563

  8. Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part III: Clinical and analytical recommendations for the study of monoclonal gammopathies by MALDI-TOF mass spectrometry

    Clinical Chemistry and Laboratory Medicine, Vol. 64, Núm. 3, pp. 586-599

2025

  1. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma

    Blood Advances, Vol. 9, Núm. 3, pp. 571-582

  2. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy

    American Journal of Hematology, Vol. 100, Núm. 1, pp. 93-102

  3. Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

    Journal of Clinical Oncology, Vol. 43, Núm. 24, pp. 2679-2691

  4. Factors Increasing the Risk of Infection in Patients With Multiple Myeloma: From Biology to Prevention

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 25, Núm. 10, pp. e844-e856.e1

  5. High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

    Blood, Vol. 146, Núm. 15, pp. 1747-1758

  6. High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy

    HemaSphere, Vol. 9, Núm. 4

  7. Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial

    The Lancet Haematology, Vol. 12, Núm. 8, pp. e588-e598

  8. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 25, Núm. 7, pp. 494-504

  9. Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform

    HemaSphere, Vol. 9, Núm. 10

  10. Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h

    Frontiers in Immunology, Vol. 16

  11. Minimally Invasive Assessment of Peripheral Residual Disease during Maintenance or Observation in Transplant-Eligible Patients with Multiple Myeloma

    Journal of Clinical Oncology, Vol. 43, Núm. 2, pp. 125-132

  12. Retrospective, observational study to describe the clinical characteristics, management, and outcomes of bispecific anti-gprc5d antibody in patients with relapsed refractory multiple myeloma treated outside clinical trials in Spain.

    Journal of Clinical Oncology, Vol. 43, pp. e19542-e19542